• Reported GAAP EPS of $0.27 up 12.50% YoY • Reported revenue of $32.24M down -0.24% YoY • OptimizeRx is updating its fiscal year 2026 guidance, expecting revenue between $109M and $114M, with Adjusted EBITDA projected to be between $21M and $25M.
Bullish
OptimizeRx achieved strong full year revenue growth and adjusted EBITDA, met its "Rule of 40" benchmark, and authorized a $10M share repurchase program.
Bearish
OptimizeRx faces increased market volatility and customer caution due to MFN pricing, a decline in net revenue retention, and risks from customer concentration and evolving technology.